Cargando…
MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease characterized by variable expressivity, age penetrance, and a high heterogeneity. The transcriptional profile (miRNAs, mRNAs), epigenetic modifications, and posttranslational modifications seem to be highly relevant for the onset of...
Autores principales: | Roma-Rodrigues, Catarina, Raposo, Luís R., Fernandes, Alexandra R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609405/ https://www.ncbi.nlm.nih.gov/pubmed/26504850 http://dx.doi.org/10.1155/2015/983290 |
Ejemplares similares
-
Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2014) -
MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy
por: Chiti, Enrica, et al.
Publicado: (2021) -
Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?
por: Abdulmawjood, Bilal, et al.
Publicado: (2021) -
Neutrophils and COVID-19: The road so far
por: Cavalcante-Silva, Luiz Henrique Agra, et al.
Publicado: (2021) -
Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
por: Fang, Lu, et al.
Publicado: (2015)